Investigate stability of RNA interference in human lymphocytes
研究人类淋巴细胞中 RNA 干扰的稳定性
基本信息
- 批准号:7837305
- 负责人:
- 金额:$ 23.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAffectAnimal ModelAnimalsApoptosisBasic ScienceBiological ModelsCCR5 geneCellsChemokine (C-C Motif) Receptor 5Chronic DiseaseCytoprotectionDataDevelopmentDown-RegulationFollow-Up StudiesFutureGene ExpressionGeneticGenomeGoalsHIV-1Hematopoietic stem cellsHumanIn VitroLentivirus VectorLymphocyteLymphoid CellMaintenanceMammalian CellMediatingModelingPathway interactionsPopulationProcessPublic HealthRNA InterferenceRelative (related person)ResearchResearch PersonnelRetroviral VectorSmall Interfering RNAStem cell transplantT-LymphocyteTechnologyTestingTherapeuticTherapeutic InterventionTimeToxic effectbasecancer therapycellular transductioncytotoxiccytotoxicityexperiencegene therapyimmunoregulationin vivomouse modelnovelperipheral bloodprogramsreconstitutionsmall hairpin RNAtherapeutic genetransgene expressionvector
项目摘要
DESCRIPTION (provided by applicant): Our overall hypothesis is that RNA interference (RNAi) can be developed to reduce specific gene expression over long-term without toxic effects in human lymphocytes. RNAi using siRNA to inhibit specific gene expression is a powerful and promising technology for both basic research and therapeutic intervention. However, our results and several recent studies have shown unintended nonspecific cytotoxic effects associated with this technology in mammalian cells raising a concern for the long term use of the RNAi in therapeutic applications in humans. The cytotoxic effects were attributed at least in part to apoptosis, although other mechanisms are also possible. The cytotoxicity was associated with higher levels of shRNA expression. Based upon these results, we hypothesized that that the levels of shRNA are important for determining whether a given shRNA will be cytotoxic or not and that optimization of those levels can yield shRNAs that are both effective and not or minimally cytotoxic. We will also address whether the cell localization of the shRNA and/or its pathway for processing can affect the extent of cytotoxicity within cells. Through our proposed studies we will understand the effects of shRNA expression in mature lymphoid cells in vitro as well as the effects on the differentiation of the lymphocyte populations in an in vivo setting. We will minimize the cytotoxic effect and maximize stable and effective function of RNAi in primary T-lymphocytes. The relevance of this research to public health. RNA interference is a powerful and promising technology to inhibit specific gene expression for both basic research and therapeutic intervention. The inhibition of specific gene expression needs to be effective without unintended side effects. This proposal propose to study the effects of RNAi in human T lymphocytes to maximize the RNAi effect and minimize side effects.
描述(由申请人提供):我们的总体假设是,可以开发RNA干扰(RNAi)来长期降低特定基因表达,而不会对人淋巴细胞产生毒性作用。利用siRNA抑制特异性基因表达的RNAi技术是一种强有力的基础研究和治疗干预技术。然而,我们的结果和最近的几项研究表明,在哺乳动物细胞中与该技术相关的非特异性细胞毒性作用引起了对RNAi在人类治疗应用中长期使用的担忧。细胞毒性作用至少部分归因于细胞凋亡,尽管其他机制也是可能的。细胞毒性与较高水平的shRNA表达相关。基于这些结果,我们假设shRNA的水平对于确定给定的shRNA是否具有细胞毒性是重要的,并且这些水平的优化可以产生既有效又无细胞毒性或具有最小细胞毒性的shRNA。我们还将讨论shRNA的细胞定位和/或其加工途径是否会影响细胞内细胞毒性的程度。通过我们提出的研究,我们将了解shRNA表达在体外成熟淋巴细胞中的作用,以及在体内环境中对淋巴细胞群体分化的作用。我们将最大限度地减少细胞毒性效应,并最大限度地提高RNAi在原代T淋巴细胞中的稳定和有效功能。这项研究与公共卫生的相关性。RNA干扰是一种有效的、有前途的抑制特异性基因表达的技术,可用于基础研究和治疗干预。特定基因表达的抑制需要是有效的,没有意外的副作用。该提案建议研究RNAi在人类T淋巴细胞中的作用,以最大限度地提高RNAi效果并最大限度地减少副作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dong Sung An其他文献
Dong Sung An的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dong Sung An', 18)}}的其他基金
Modulation of repopulation of anti HIV-1 gene-modified cells to enhance efficacy and safety
调节抗 HIV-1 基因修饰细胞的再增殖以提高功效和安全性
- 批准号:
10614651 - 财政年份:2020
- 资助金额:
$ 23.59万 - 项目类别:
Modulation of repopulation of anti HIV-1 gene-modified cells to enhance efficacy and safety
调节抗 HIV-1 基因修饰细胞的再增殖以提高功效和安全性
- 批准号:
10160822 - 财政年份:2020
- 资助金额:
$ 23.59万 - 项目类别:
Modulation of repopulation of anti HIV-1 gene-modified cells to enhance efficacy and safety
调节抗 HIV-1 基因修饰细胞的再增殖以提高功效和安全性
- 批准号:
10468655 - 财政年份:2020
- 资助金额:
$ 23.59万 - 项目类别:
Efficient Sendai virus mediated CRISPR/Cas9 gene editing to protect hematopoietic stem cells from HIV
高效仙台病毒介导的 CRISPR/Cas9 基因编辑保护造血干细胞免受 HIV 感染
- 批准号:
10402835 - 财政年份:2018
- 资助金额:
$ 23.59万 - 项目类别:
Efficient Sendai virus mediated CRISPR/Cas9 gene editing to protect hematopoietic stem cells from HIV
高效仙台病毒介导的 CRISPR/Cas9 基因编辑保护造血干细胞免受 HIV 感染
- 批准号:
10171759 - 财政年份:2018
- 资助金额:
$ 23.59万 - 项目类别:
Genetic protection of hematopoietic stem cells for stable HIV control
造血干细胞的基因保护以稳定艾滋病毒控制
- 批准号:
8410026 - 财政年份:2012
- 资助金额:
$ 23.59万 - 项目类别:
Genetic protection of hematopoietic stem cells for stable HIV control
造血干细胞的基因保护以稳定艾滋病毒控制
- 批准号:
8881091 - 财政年份:2012
- 资助金额:
$ 23.59万 - 项目类别:
Genetic protection of hematopoietic stem cells for stable HIV control
造血干细胞的基因保护以稳定艾滋病毒控制
- 批准号:
8703001 - 财政年份:2012
- 资助金额:
$ 23.59万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 23.59万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 23.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 23.59万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 23.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 23.59万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 23.59万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 23.59万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 23.59万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 23.59万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 23.59万 - 项目类别:
Discovery Grants Program - Individual